Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
8.77
-0.36 (-3.94%)
At close: Mar 24, 2026, 4:00 PM EDT
8.88
+0.11 (1.25%)
Pre-market: Mar 25, 2026, 6:40 AM EDT

Telix Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
803.79516.55332.98108.955.52
Revenue Growth (YoY)
55.61%55.13%205.64%1873.24%37.53%
Cost of Revenue
377.36180.39123.4544.354.63
Gross Profit
426.44336.16209.5364.60.89
Selling, General & Admin
237.15157.9489.3856.824.64
Research & Development
171.25127.9385.3254.9134.97
Other Operating Expenses
11.744.89-23.83-10.074.7
Total Operating Expenses
420.13290.76150.87101.6464.31
Operating Income
29.7855.1811.01-62.56-54.69
Interest Income
5.837.180.670-
Interest Expense
-40.87-24.44-9.09-4.55-3.79
Total Non-Operating Income (Expense)
-35.04-17.26-8.41-4.55-3.79
Pretax Income
-5.2737.922.59-67.11-58.49
Provision for Income Taxes
1.864.23-1.613.71-0.03
Net Income
-7.1333.694.21-70.83-58.52
Net Income to Common
-7.1333.694.21-70.83-58.52
Net Income Growth
-700.50%---
Shares Outstanding (Basic)
338331319311282
Shares Outstanding (Diluted)
338345324311282
Shares Change (YoY)
-2.12%6.64%4.21%10.08%9.69%
EPS (Basic)
-0.020.100.01-0.23-0.21
EPS (Diluted)
-0.020.100.01-0.23-0.21
EPS Growth
-650.77%---
Free Cash Flow
-42.9918.377.97-48.32-44.1
Free Cash Flow Growth
-130.64%---
Free Cash Flow Per Share
-0.130.050.02-0.16-0.16
Gross Margin
53.05%65.08%62.93%59.29%16.13%
Operating Margin
3.70%10.68%3.31%-57.42%-990.61%
Profit Margin
-0.89%6.52%1.26%-65.01%-1059.90%
FCF Margin
-5.35%3.56%2.39%-44.35%-798.67%
EBITDA
51.1960.4615.16-62.56-54.69
EBITDA Margin
6.37%11.70%4.55%-57.42%-990.61%
EBIT
29.7855.1811.01-62.56-54.69
EBIT Margin
3.70%10.68%3.31%-57.42%-990.61%
Effective Tax Rate
-35.30%11.16%-62.22%-5.53%0.06%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q